ELSALYS BIOTECH has developed a program based on the anti-angiogenic properties of the anti-CD160 antibody to treat vascular eye diseases and in particular Age-related Macular Degeneration (AMD).

Since this therapeutic domain is outside of the strategic field of activity of the company, ELSALYS BIOTECH is seeking for partnerships for the clinical development and the commercialization of ELB011.

Mechanism of action of ELB011

ELSALYS BIOTECH has already performed preclinical studies with very promising results:

• In rabbits, treatment with anti-CD160 blocks the formation of new blood vessels, similar to anti-VEGF agents, in a model of induced corneal angiogenesis
• A combination treatment between an anti-CD160 and an anti-VEGF potentiates the anti-angiogenic effect, suggesting that the two biological pathways are at least partially independent
• A first generation anti-CD160 limits the number of severe lesions induced with a laser and promotes their healing